Lisi Group (FII) H2 2025 earnings summary

Executive summary

• Achieved significant organic growth for the fourth consecutive year, with revenue up 11.5% year-over-year to a record €1,747.9M, driven by strong aerospace performance and strategic portfolio refocusing.

• EBIT rose 63.2% to €161.0M, and net income surged 149.6% to €139.7M, 2.5 times higher than the prior year.

• Sale of LISI MEDICAL division for €270.4M, with reinvestment and potential earn-outs, significantly reduced net financial debt.

• Joined SBF 120 and CAC Mid 60 indices, reflecting increased market recognition and confidence.

Financial highlights

• Consolidated revenue reached €1,747.9M, up 8.7% from €1,608.7M in 2024.

• EBITDA rose 42.5% to €261.5M (15.0% margin), and EBIT increased 63.2% to €161.0M (9.2% margin).

• Net earnings surged 149.6% to €139.7M.

• Free cash flow was €56.1M after €99.9M in net industrial investments.

• Net financial debt dropped to €233.7M (0.9x EBITDA), down from €488.5M (2.3x EBITDA) in 2024.

Outlook and guidance

• Aerospace division expects continued strong demand, with a robust order book and focus on capacity expansion and productivity.

• Automotive division to maintain agility, adapt cost structure, and focus on high-value products amid low market visibility.

• Group aims to improve key financial indicators and generate positive free cash flow, assuming stable macroeconomic conditions.